Vaccine effects on COVID-19 infection with bivalent boosting by age group
Copyright © 2023 Elsevier Ltd. All rights reserved..
This paper examines time-series vaccine effectiveness on COVID-19 infection with/without a bivalent booster dose by 6 age groups such as 18-29, 30-49, 50-64, 65-79, 80+, and all_ages respectively. CDC's COVID data on rates of COVID-19 cases and deaths by updated (bivalent) booster status was used in this study. This result concludes that there is no difference between vaccines with or without a bivalent booster dose for preventing COVID-19 infection in 6 age groups 18-29, 30-49, 50-64, 65-79, 80+, and all_ages. Vaccination is effective in two age groups of 65-79 and 80+ for preventing COVID-19 infection. However, vaccine effectiveness against COVID-19 infection has not been confirmed in the 18-29 and 30-49 age groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 73(2024) vom: 06. März, Seite 101039 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takefuji, Yoshiyasu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bivalent booster |
|---|
| Anmerkungen: |
Date Completed 08.03.2024 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drup.2023.101039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36659902X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36659902X | ||
| 003 | DE-627 | ||
| 005 | 20240308232307.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drup.2023.101039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM36659902X | ||
| 035 | |a (NLM)38169273 | ||
| 035 | |a (PII)S1368-7646(23)00122-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takefuji, Yoshiyasu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine effects on COVID-19 infection with bivalent boosting by age group |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a This paper examines time-series vaccine effectiveness on COVID-19 infection with/without a bivalent booster dose by 6 age groups such as 18-29, 30-49, 50-64, 65-79, 80+, and all_ages respectively. CDC's COVID data on rates of COVID-19 cases and deaths by updated (bivalent) booster status was used in this study. This result concludes that there is no difference between vaccines with or without a bivalent booster dose for preventing COVID-19 infection in 6 age groups 18-29, 30-49, 50-64, 65-79, 80+, and all_ages. Vaccination is effective in two age groups of 65-79 and 80+ for preventing COVID-19 infection. However, vaccine effectiveness against COVID-19 infection has not been confirmed in the 18-29 and 30-49 age groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bivalent booster | |
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 4 | |a Vaccine efficacy | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy |d 1995 |g 73(2024) vom: 06. März, Seite 101039 |w (DE-627)NLM097532371 |x 1532-2084 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2024 |g day:06 |g month:03 |g pages:101039 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drup.2023.101039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2024 |b 06 |c 03 |h 101039 | ||